TY  - GEN
AU  - Kloner,Robert A
TI  - Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction
SN  - 1524-4539
PY  - 2005///0621
KW  - 3',5'-Cyclic-GMP Phosphodiesterases
KW  - Adrenergic alpha-Antagonists
KW  - pharmacology
KW  - Arteriosclerosis
KW  - complications
KW  - Blood Pressure
KW  - drug effects
KW  - Carbolines
KW  - adverse effects
KW  - Contraindications
KW  - Coronary Disease
KW  - Cyclic GMP
KW  - metabolism
KW  - Cyclic Nucleotide Phosphodiesterases, Type 5
KW  - Drug Interactions
KW  - Endothelium, Vascular
KW  - Erectile Dysfunction
KW  - drug therapy
KW  - Heart Rate
KW  - Humans
KW  - Hypotension
KW  - chemically induced
KW  - Imidazoles
KW  - Isosorbide Dinitrate
KW  - analogs & derivatives
KW  - Male
KW  - Molecular Structure
KW  - Myocardial Infarction
KW  - Nitric Oxide Donors
KW  - Nitroglycerin
KW  - Phosphodiesterase Inhibitors
KW  - Phosphoric Diester Hydrolases
KW  - Piperazines
KW  - Purines
KW  - Randomized Controlled Trials as Topic
KW  - Sildenafil Citrate
KW  - Sulfones
KW  - Tadalafil
KW  - Triazines
KW  - Vardenafil Dihydrochloride
KW  - Vasodilation
KW  - Vasodilator Agents
N1  - Publication Type: Journal Article; Review
UR  - https://doi.org/10.1161/01.CIR.0000146906.42375.D3
ER  -